BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

...with vehicle. Next steps could include testing the compound in mouse models of BRAF-mutant melanoma. BioMed Valley Discoveries Inc....
BioCentury | Jan 5, 2018
Clinical News

BioMed Valley's ulixertinib leads to partial responses in Phase I for solid tumors

...MAPK1; ERK-2)/MAPK3 (ERK-1) inhibitor. The candidate has Fast Track designation from FDA to treat melanoma. BioMed Valley Discoveries Inc....
...Phase II dose; pharmacokinetics and preliminary tumor response Status: Phase I data Milestone: NA Jaime De Leon BVD-523 ulixertinib BioMed Valley Discoveries Inc. MAP...
BioCentury | Aug 20, 2015
Finance

Gladstone adds for profit

...at the negotiating table." Funding the gap Freedman said Gladstone modeled Cure Network Ventures after BioMed Valley...
...unlike Cure Network, BVD doesn’t rely on partnerships with venture philanthropists because its funding from BioMed Valley...
...is appropriately carved out," he said. Companies and Institutions Mentioned BioMed Valley Corp., Kansas City, Mo. BioMed Valley Discoveries Inc....
BioCentury | Sep 11, 2014
Distillery Therapeutics

Indication: Cancer

...7(35); doi:10.1038/scibx.2014.1037 Published online Sept. 11, 2014 Patented by The Johns Hopkins University; licensed to BioMed Valley Discoveries Inc....
BioCentury | Jun 12, 2014
Targets & Mechanisms

Putting SMYD3 on the MAP

...II AstraZeneca; Bayer Refametinib (BAY 86-9766) Pancreatic and biliary duct cancers MEK1; MEK2 Phase I/II BioMed Valley Discoveries Inc....
BioCentury | Sep 15, 2011
Distillery Techniques

Technology: Drug platforms

...SciBX 4(36); doi:10.1038/scibx.2011.1029 Published online Sept. 15, 2011 Patent applications filed; available for licensing from BioMed Valley Discoveries Inc....
...research organization established and funded by the Stowers Institute for Medical Research Contact: Saurabh Saha, BioMed Valley Discoveries Inc....
Items per page:
1 - 6 of 6
BioCentury | Jul 10, 2018
Distillery Therapeutics

Cancer

...with vehicle. Next steps could include testing the compound in mouse models of BRAF-mutant melanoma. BioMed Valley Discoveries Inc....
BioCentury | Jan 5, 2018
Clinical News

BioMed Valley's ulixertinib leads to partial responses in Phase I for solid tumors

...MAPK1; ERK-2)/MAPK3 (ERK-1) inhibitor. The candidate has Fast Track designation from FDA to treat melanoma. BioMed Valley Discoveries Inc....
...Phase II dose; pharmacokinetics and preliminary tumor response Status: Phase I data Milestone: NA Jaime De Leon BVD-523 ulixertinib BioMed Valley Discoveries Inc. MAP...
BioCentury | Aug 20, 2015
Finance

Gladstone adds for profit

...at the negotiating table." Funding the gap Freedman said Gladstone modeled Cure Network Ventures after BioMed Valley...
...unlike Cure Network, BVD doesn’t rely on partnerships with venture philanthropists because its funding from BioMed Valley...
...is appropriately carved out," he said. Companies and Institutions Mentioned BioMed Valley Corp., Kansas City, Mo. BioMed Valley Discoveries Inc....
BioCentury | Sep 11, 2014
Distillery Therapeutics

Indication: Cancer

...7(35); doi:10.1038/scibx.2014.1037 Published online Sept. 11, 2014 Patented by The Johns Hopkins University; licensed to BioMed Valley Discoveries Inc....
BioCentury | Jun 12, 2014
Targets & Mechanisms

Putting SMYD3 on the MAP

...II AstraZeneca; Bayer Refametinib (BAY 86-9766) Pancreatic and biliary duct cancers MEK1; MEK2 Phase I/II BioMed Valley Discoveries Inc....
BioCentury | Sep 15, 2011
Distillery Techniques

Technology: Drug platforms

...SciBX 4(36); doi:10.1038/scibx.2011.1029 Published online Sept. 15, 2011 Patent applications filed; available for licensing from BioMed Valley Discoveries Inc....
...research organization established and funded by the Stowers Institute for Medical Research Contact: Saurabh Saha, BioMed Valley Discoveries Inc....
Items per page:
1 - 6 of 6